NZ203416A - Oral antidiabetic compositions containing 5-substituted oxazolidine-2,4-dione derivatives and hypoglycaemic sulphonylureas - Google Patents

Oral antidiabetic compositions containing 5-substituted oxazolidine-2,4-dione derivatives and hypoglycaemic sulphonylureas

Info

Publication number
NZ203416A
NZ203416A NZ203416A NZ20341683A NZ203416A NZ 203416 A NZ203416 A NZ 203416A NZ 203416 A NZ203416 A NZ 203416A NZ 20341683 A NZ20341683 A NZ 20341683A NZ 203416 A NZ203416 A NZ 203416A
Authority
NZ
New Zealand
Prior art keywords
compound
chlorpropamide
methoxy
glipizide
oxazolidine
Prior art date
Application number
NZ203416A
Other languages
English (en)
Inventor
M Morville
M G Page
R C Schnur
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of NZ203416A publication Critical patent/NZ203416A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NZ203416A 1982-03-01 1983-02-28 Oral antidiabetic compositions containing 5-substituted oxazolidine-2,4-dione derivatives and hypoglycaemic sulphonylureas NZ203416A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35378282A 1982-03-01 1982-03-01
US45032082A 1982-12-20 1982-12-20

Publications (1)

Publication Number Publication Date
NZ203416A true NZ203416A (en) 1985-08-16

Family

ID=26998096

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ203416A NZ203416A (en) 1982-03-01 1983-02-28 Oral antidiabetic compositions containing 5-substituted oxazolidine-2,4-dione derivatives and hypoglycaemic sulphonylureas

Country Status (12)

Country Link
EP (1) EP0091193B1 (enExample)
AU (1) AU553330B2 (enExample)
CA (1) CA1194800A (enExample)
DE (1) DE3363577D1 (enExample)
FI (1) FI830653A7 (enExample)
GR (1) GR78120B (enExample)
HU (1) HU188015B (enExample)
IE (1) IE54622B1 (enExample)
NO (1) NO830685L (enExample)
NZ (1) NZ203416A (enExample)
PH (1) PH18466A (enExample)
PT (1) PT76299B (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988009661A1 (en) * 1987-06-10 1988-12-15 Pfizer Inc. Oxazolidin-2-one derivatives as hypoglycemic agents
US10188617B2 (en) 2013-03-12 2019-01-29 The Board Of Trustees Of The Leland Stanford Junior University Modulation of cellular DNA repair activity to intercept malignancy

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4367234A (en) * 1980-07-28 1983-01-04 Pfizer Inc. Hypoglycemic 5-substituted oxazolidine-2,4-diones
GB2080803B (en) * 1980-07-28 1984-01-18 Pfizer Hypoglycemic 5-substituted oxazolidine-2,4-diones

Also Published As

Publication number Publication date
PT76299A (en) 1983-03-01
FI830653L (fi) 1983-09-02
FI830653A7 (fi) 1983-09-02
IE54622B1 (en) 1989-12-20
PH18466A (en) 1985-07-18
EP0091193A2 (en) 1983-10-12
AU1189783A (en) 1983-09-08
EP0091193B1 (en) 1986-05-21
DE3363577D1 (en) 1986-06-26
AU553330B2 (en) 1986-07-10
PT76299B (en) 1986-03-27
EP0091193A3 (en) 1984-07-11
NO830685L (no) 1983-09-02
HU188015B (en) 1986-03-28
FI830653A0 (fi) 1983-02-28
IE830412L (en) 1983-09-01
GR78120B (enExample) 1984-09-26
CA1194800A (en) 1985-10-08

Similar Documents

Publication Publication Date Title
US5929066A (en) Chromium/biotin treatment of Type II diabetes
CA2024188C (en) Method of treating premature ejaculation using sertraline
US3636219A (en) Anticholinergic compositions containing certain thiazolines or imidazolines
AU737038B2 (en) Anti-viral pharmaceutical compositions containing saturated 1,2-dithiaheterocyclic compounds and uses thereof
CA2297834C (en) Chromium/biotin treatment of type ii diabetes
WO2001030749B1 (en) Novel compounds
SE469059B (sv) Anvaendning av acyloxialkanoylkolinsalt foer framstaellning av laekemedel foer behandling av neuropsykiatriska symtom som aatfoeljer demens
EP0091193B1 (en) Antidiabetic compositions
US5011841A (en) Treatment of depression
EP0443028B1 (en) Non-injection carcinostatic agent for suppressing occurrence of inflammation due to 5-fluorouracil and method for curing cancer
BG64817B1 (bg) Комбинация от тиазолидиндион и сулфонилуреа, състав и използване
HU204433B (en) Process for producing pharmaceutical composition against artheriosclerosis containing dl-5- /2-benzyl-3,4-dihydro-2h-benzopiran-6-yl)-methyl/-thiazolidine- -2,4-dion
CA2024181C (en) Method of treating chemical dependencies using sertraline
JP2004513962A (ja) 抗糖尿病作用を有する新規な薬剤組成物およびその製剤方法
KR20080028415A (ko) ＰＰＡＲγ 애고니스트를 함유하는 의약 조성물
JPS58174321A (ja) 抗糖尿病組成物
US5464869A (en) Use of dimercaptan acids, salts and metabolites thereof as antiretroviral treatments
OKE et al. The oral hypoglycemic activity of 2, 5-dioxamide derivatives of 1, 3, 4-thiadiazole
EP0146338A2 (en) A blood accelerator 2, 3-diphosphoglyceric acid
AU592097B2 (en) Method for the treatment and/or prophylaxis of hyperglycaemia
AU2002302012B2 (en) Chromim/biotin treatment of type II diabetes
HU183090B (en) Process for preparing a diuretic composition
HU208483B (en) Process for producing pharmaceutical composition
Creutzfeldt The discovery of the oral treatment of diabetes mellitus with sulphonylureas
JPS6152805B2 (enExample)